DE69635301D1 - Verminderung von adhäsionen durch gesteuerte verabreichung von aktivsauerstoffinhibitoren - Google Patents

Verminderung von adhäsionen durch gesteuerte verabreichung von aktivsauerstoffinhibitoren

Info

Publication number
DE69635301D1
DE69635301D1 DE69635301T DE69635301T DE69635301D1 DE 69635301 D1 DE69635301 D1 DE 69635301D1 DE 69635301 T DE69635301 T DE 69635301T DE 69635301 T DE69635301 T DE 69635301T DE 69635301 D1 DE69635301 D1 DE 69635301D1
Authority
DE
Germany
Prior art keywords
adhesions
inhibitors
active
surfactures
reduction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69635301T
Other languages
English (en)
Other versions
DE69635301T2 (de
Inventor
Keith Baker
Arthur J Coury
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Application granted granted Critical
Publication of DE69635301D1 publication Critical patent/DE69635301D1/de
Publication of DE69635301T2 publication Critical patent/DE69635301T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE69635301T 1995-03-24 1996-03-20 Verminderung von adhäsionen durch gesteuerte verabreichung von aktivsauerstoffinhibitoren Expired - Lifetime DE69635301T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US410219 1989-09-21
US41021995A 1995-03-24 1995-03-24
PCT/US1996/003813 WO1996029987A1 (en) 1995-03-24 1996-03-20 Reduction of adhesions using controlled delivery of active oxygen inhibitors

Publications (2)

Publication Number Publication Date
DE69635301D1 true DE69635301D1 (de) 2006-03-02
DE69635301T2 DE69635301T2 (de) 2006-07-20

Family

ID=23623783

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69635301T Expired - Lifetime DE69635301T2 (de) 1995-03-24 1996-03-20 Verminderung von adhäsionen durch gesteuerte verabreichung von aktivsauerstoffinhibitoren

Country Status (8)

Country Link
US (2) US5785993A (de)
EP (1) EP0814774B1 (de)
JP (1) JP3145409B2 (de)
AT (1) ATE306903T1 (de)
AU (1) AU704222B2 (de)
CA (1) CA2215317C (de)
DE (1) DE69635301T2 (de)
WO (1) WO1996029987A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0814774B1 (de) * 1995-03-24 2005-10-19 Genzyme Corporation Verminderung von adhäsionen durch gesteuerte verabreichung von aktivsauerstoffinhibitoren
US5899917A (en) * 1997-03-12 1999-05-04 Cardiosynopsis, Inc. Method for forming a stent in situ
CA2283708A1 (en) 1997-03-20 1998-09-24 Focal, Inc. Biodegradable tissue retractor
EP0887076A3 (de) * 1997-05-07 1999-03-31 Saturnus A.G. Verhinderung von Gewebeverklebung und ein dafür vorgesehenes endoskopisches System zum Aufblasen einer Körperhöhle
EP1044002A4 (de) 1997-11-07 2003-05-02 Univ Johns Hopkins Methoden zur behandlung von störungen der herzkontraktilität
US6627663B2 (en) 1998-08-03 2003-09-30 W. Jerry Easterling Noninvasive method for treating hemangiomas through transdermal delivery of calcium channel blocker agents and medicament for use in such method
US6525100B1 (en) 1998-08-03 2003-02-25 W. Jerry Easterling Composition and method for treating peyronie's disease and related fibrotic tissue disorders
US6031005A (en) * 1998-08-03 2000-02-29 Easterling; W. Jerry Composition and method for treating Peyronie's disease and related connective tissue disorders
US6197309B1 (en) * 1998-08-03 2001-03-06 Ronald E. Wheeler Prostate formula
US20080114092A1 (en) * 1998-12-04 2008-05-15 Incept Llc Adhesion barriers applicable by minimally invasive surgery and methods of use thereof
AP2002002552A0 (en) 1999-12-23 2002-06-30 Pfizer Prod Inc Pharmaceutical compositions providing enhanced drug concentrations.
CA2404157A1 (en) * 2000-03-28 2001-10-04 Robert J. Delorenzo Inhibition of a novel calcium injury current that forms in neurons during injury prevents neuronal cell death
FI20010898A0 (fi) * 2001-04-30 2001-04-30 Ylae Herttuala Seppo Ekstrasellulaarinen superoksididismutaasi (EC-SOD) geeniterapia restenoosoin ehkäisemiseksi
WO2003092727A1 (en) * 2002-04-30 2003-11-13 Fit Biotech Oyj Plc Medical device
EP1534191A4 (de) * 2002-08-20 2010-11-03 Exactech Inc Zusammensetzung zum tragen und abgeben von das knochenwachstum induzierendem material und verfahren zur herstellung und applikation der zusammensetzung
AU2003279823A1 (en) 2002-10-28 2004-05-25 Northgate Technologies Inc. Dual-capacity insufflator tube
US7654975B2 (en) 2003-04-24 2010-02-02 Northgate Technologies, Inc. Mixed-gas insufflation system
US7955616B2 (en) * 2003-09-23 2011-06-07 Orthocon, Inc. Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects
EP2462958A3 (de) * 2003-09-23 2012-09-19 Orthocon Inc. Saugfähige Implantate und Verfahren zu ihrer Verwendung bei der Hämostase und der Behandlung von Knochendefekten
EP1673125B1 (de) 2003-10-07 2009-12-23 Northgate Technologies Incorporated System für die abgabe einer substanz in eine körperhöhle
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
US7332179B2 (en) * 2003-12-12 2008-02-19 Kimberly-Clark Worldwide, Inc. Tissue products comprising a cleansing composition
US20050244480A1 (en) * 2004-04-30 2005-11-03 Kimberly-Clark Worldwide, Inc. Pre-wipes for improving anal cleansing
US20060140899A1 (en) * 2004-12-28 2006-06-29 Kimberly-Clark Worldwide, Inc. Skin cleansing system comprising an anti-adherent formulation and a cationic compound
US7642395B2 (en) * 2004-12-28 2010-01-05 Kimberly-Clark Worldwide, Inc. Composition and wipe for reducing viscosity of viscoelastic bodily fluids
US9119901B2 (en) 2005-04-28 2015-09-01 Warsaw Orthopedic, Inc. Surface treatments for promoting selective tissue attachment to medical impants
US8414907B2 (en) 2005-04-28 2013-04-09 Warsaw Orthopedic, Inc. Coatings on medical implants to guide soft tissue healing
JP2008543967A (ja) * 2005-06-28 2008-12-04 ライフ サイエンス インベンシヨンズ リミテッド 炎症性皮膚病変を治療するためのスーパーオキシドジスムターゼとカタラーゼとの混合物の使用
JP2009523118A (ja) * 2005-11-14 2009-06-18 ユニバーシティー、オブ、デラウェア 新規ハイドロゲルおよびそれらの使用
US7706852B2 (en) 2006-01-30 2010-04-27 Nellcor Puritan Bennett Llc System and method for detection of unstable oxygen saturation
JP2009545417A (ja) 2006-08-04 2009-12-24 ノースゲート テクノロジーズ インコーポレイテッド 体内へアクセスするための留置ポート
US20080241270A1 (en) * 2007-03-30 2008-10-02 Neal Robert A Fluid composition for inhibiting surgical adhesion formation and related method of production
AU2010314994B2 (en) 2009-11-09 2016-10-06 Spotlight Technology Partners Llc Fragmented hydrogels
CN102695500A (zh) 2009-11-09 2012-09-26 聚光灯技术合伙有限责任公司 多糖基水凝胶
EP2922919B1 (de) 2012-11-21 2020-03-25 University Of Louisville Research Foundation, Inc. Zusammensetzungen und verfahren zur reduzierung von oxidativen schäden
US9572595B1 (en) 2014-03-05 2017-02-21 Northgate Technologies Inc. In-dwelling port for access into a body
WO2016130478A1 (en) 2015-02-09 2016-08-18 University Of Louisville Research Foundation, Inc. Ophthalmic compositions and methods for reducing oxidative damage to an eye lens
US10590257B2 (en) 2016-09-26 2020-03-17 The Board Of Trustees Of The Leland Stanford Junior University Biomimetic, moldable, self-assembled cellulose silica-based trimeric hydrogels and their use as viscosity modifying carriers in industrial applications
CN106468668B (zh) * 2016-09-28 2019-03-12 北京凯视佳光电设备有限公司 工业相机圆柱检测方法
WO2019152917A1 (en) 2018-02-02 2019-08-08 Galen Therapeutics Llc Apparatus and method for protecting neurons and reducing inflammation and scarring

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3784585A (en) * 1971-10-21 1974-01-08 American Cyanamid Co Water-degradable resins containing recurring,contiguous,polymerized glycolide units and process for preparing same
US4371519A (en) * 1972-06-05 1983-02-01 Hettinger Jr William P Methods of treating cellular tissue
US4897308A (en) * 1975-06-30 1990-01-30 L'oreal Compositions comprising aqueous dispersions of lipid spheres
US4563349A (en) * 1980-07-30 1986-01-07 Takeda Chemical Industries, Ltd. Superoxide dismutase, its immobilized form, and their production and use
ATE37983T1 (de) * 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
US5286763A (en) * 1983-03-22 1994-02-15 Massachusetts Institute Of Technology Bioerodible polymers for drug delivery in bone
JPS6014861A (ja) * 1983-07-05 1985-01-25 株式会社日本メデイカル・サプライ 癒着防止材
EP0656418B1 (de) * 1983-10-03 2002-12-04 Chiron Corporation Klonieren von Superoxiddismutase und Expression in Mikroorganismen
US4511478A (en) * 1983-11-10 1985-04-16 Genetic Systems Corporation Polymerizable compounds and methods for preparing synthetic polymers that integrally contain polypeptides
US4873292A (en) * 1984-12-28 1989-10-10 Research Development Corporation Of Japan Antithrombogenic synthetic polymer and process for its preparation
US4760051A (en) * 1985-01-24 1988-07-26 Pickart Loren R Use of GHL-Cu as a wound-healing and anti-inflammatory agent
CS254355B1 (en) * 1985-04-10 1988-01-15 Vladimir Saudek Soluble and biodegradatable copolymeres activated for bond of biologicaly active substances
JPH084504B2 (ja) * 1985-04-26 1996-01-24 味の素株式会社 安定化ス−パ−オキサイドジスムタ−ゼ
IN166447B (de) * 1985-11-27 1990-05-12 Ethicon Inc
US4889722A (en) * 1985-12-16 1989-12-26 Ethicon, Inc. Method for inhibiting post-surgical adhesion formation by the topical administration of tissue plasminogen activator
US4806621A (en) * 1986-01-21 1989-02-21 Massachusetts Institute Of Technology Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article
US4976959A (en) * 1986-05-12 1990-12-11 Burroughs Wellcome Co. T-PA and SOD in limiting tissue damage
US5160745A (en) * 1986-05-16 1992-11-03 The University Of Kentucky Research Foundation Biodegradable microspheres as a carrier for macromolecules
US4741872A (en) * 1986-05-16 1988-05-03 The University Of Kentucky Research Foundation Preparation of biodegradable microspheres useful as carriers for macromolecules
IT1198449B (it) * 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani Esteri di alcoli polivalenti di acido ialuronico
US5547988B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Alleviating signs of dermatological aging with glycolic acid lactic acid or citric acid
US5260204A (en) * 1987-03-14 1993-11-09 Boehringer Ingelheim International Gmbh Human manganese superoxide dismutase (hMn-SOD)
US5227405A (en) * 1987-03-31 1993-07-13 Duke University Superoxide dismutase mimic
US5223538A (en) * 1987-03-31 1993-06-29 Duke University Superoxide dismutase mimic
DE3853493T2 (de) * 1987-05-28 1995-07-27 Hiroshi Maeda Superoxid-Dismutase-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel.
IL82834A (en) * 1987-06-09 1990-11-05 Yissum Res Dev Co Biodegradable polymeric materials based on polyether glycols,processes for the preparation thereof and surgical artiicles made therefrom
HU209955B (en) * 1987-07-01 1994-12-28 Genentech Inc Process for producing pharmaceutical compositions containing tissue- -plasminogen-activator of poor solubility for inhibiting production and regeneration of deformities
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US4804691A (en) * 1987-08-28 1989-02-14 Richards Medical Company Method for making a biodegradable adhesive for soft living tissue
US5364622A (en) * 1987-12-04 1994-11-15 Dr. Karl Thomae Gmbh Methods for preventing adhesions to organs and parts of organs by application of tissue plasminogen activator and hydroxyethylcellulose hydrogel
US4888413A (en) * 1988-01-11 1989-12-19 Domb Abraham J Poly(propylene glycol fumarate) compositions for biomedical applications
US4898734A (en) * 1988-02-29 1990-02-06 Massachusetts Institute Of Technology Polymer composite for controlled release or membrane formation
US5057494A (en) * 1988-08-03 1991-10-15 Ethicon, Inc. Method for preventing tissue damage after an ischemic episode
US5328471A (en) * 1990-02-26 1994-07-12 Endoluminal Therapeutics, Inc. Method and apparatus for treatment of focal disease in hollow tubular organs and other tissue lumens
US5213580A (en) * 1988-08-24 1993-05-25 Endoluminal Therapeutics, Inc. Biodegradable polymeric endoluminal sealing process
US4925677A (en) * 1988-08-31 1990-05-15 Theratech, Inc. Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US4911926A (en) * 1988-11-16 1990-03-27 Mediventures Inc. Method and composition for reducing postsurgical adhesions
US5126141A (en) * 1988-11-16 1992-06-30 Mediventures Incorporated Composition and method for post-surgical adhesion reduction with thermo-irreversible gels of polyoxyalkylene polymers and ionic polysaccharides
US5135751A (en) * 1988-11-16 1992-08-04 Mediventures Incorporated Composition for reducing postsurgical adhesions
CA2004740A1 (en) * 1988-12-07 1990-06-07 Cary Linsky Low molecular weight heparin, heparinoid and hexuronyl hexosaminoglycan sulfate containing adhesion prevention barrier and process
US5108755A (en) * 1989-04-27 1992-04-28 Sri International Biodegradable composites for internal medical use
IL90193A (en) * 1989-05-04 1993-02-21 Biomedical Polymers Int Polurethane-based polymeric materials and biomedical articles and pharmaceutical compositions utilizing the same
US4994277A (en) * 1989-10-31 1991-02-19 Pfizer Hospital Products Group, Inc. Use of xanthan gum for preventing adhesions
US5175235A (en) * 1990-06-04 1992-12-29 Nova Pharmaceutical Corporation Branched polyanhydrides
EP0589871B1 (de) * 1990-02-13 2000-04-26 Ethicon, Inc. Peritoneal wirksame medikamente
US5292516A (en) * 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers
US5219564A (en) * 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
US5143731A (en) * 1990-08-07 1992-09-01 Mediventures Incorporated Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
US5217966A (en) * 1990-09-13 1993-06-08 The Regents Of The University Of California Synthetic drug molecules that mimic metalloenzymes
US5410016A (en) * 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5529914A (en) * 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
US5288502A (en) * 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres
CA2117588C (en) * 1992-02-28 1998-08-25 Jeffrey A. Hubbell Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5384333A (en) * 1992-03-17 1995-01-24 University Of Miami Biodegradable injectable drug delivery polymer
AU3972893A (en) * 1992-04-03 1993-11-08 Baylor College Of Medicine Gene therapy using the intestine
JP3579052B2 (ja) * 1993-03-23 2004-10-20 フォーカル，インコーポレイテッド 重合材料の生体組織への局部付与のための装置
JPH08509642A (ja) * 1993-04-28 1996-10-15 フォーカル，インコーポレイテッド 管腔内フォトサーモフォーミングの装置およびその方法
US5519035A (en) * 1993-07-02 1996-05-21 Cornell Research Foundation, Inc. Treatment of stroke or in anticipation of the occurrence of brain ischemia
DK0705298T3 (da) * 1993-12-01 2002-07-08 Bioartificial Gel Technologies Inc Albuminbaseret hydrogel
US5419917A (en) * 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
JP3492787B2 (ja) * 1994-04-15 2004-02-03 信越化学工業株式会社 固形製剤のコーティング用水性エマルジョンの濃縮方法
IL109539A0 (en) * 1994-05-03 1994-08-26 Yissum Res Dev Co Substained-release pharmaceutical system for the delivery of antioxidants
US5478837A (en) 1994-06-07 1995-12-26 University Of Southern California Use of quinacrine in preventing adhesion formation
US5562594A (en) * 1994-06-10 1996-10-08 Duke University Shielded mini-applicator system for radioactive source treatment of cancer of the uterine cervix
EP0814774B1 (de) * 1995-03-24 2005-10-19 Genzyme Corporation Verminderung von adhäsionen durch gesteuerte verabreichung von aktivsauerstoffinhibitoren
US5527864A (en) * 1995-08-08 1996-06-18 Suggs; Laura J. Poly(propylene fumarate-co-ethylene oxide)

Also Published As

Publication number Publication date
AU5257596A (en) 1996-10-16
CA2215317C (en) 2002-07-23
US20010046503A1 (en) 2001-11-29
AU704222B2 (en) 1999-04-15
JP3145409B2 (ja) 2001-03-12
EP0814774A1 (de) 1998-01-07
US5785993A (en) 1998-07-28
DE69635301T2 (de) 2006-07-20
EP0814774B1 (de) 2005-10-19
CA2215317A1 (en) 1996-10-03
JPH10508872A (ja) 1998-09-02
US6780427B2 (en) 2004-08-24
WO1996029987A1 (en) 1996-10-03
ATE306903T1 (de) 2005-11-15

Similar Documents

Publication Publication Date Title
DE69635301D1 (de) Verminderung von adhäsionen durch gesteuerte verabreichung von aktivsauerstoffinhibitoren
ATE238813T1 (de) Wirkstoffformulierungen mit verzögerter freisetzung
DE69425509T2 (de) Lokale verabreichung von fibrinolyse verstärkendemitteln
TR199901411T2 (xx) Analjezik etkili yeni bile�imler.
DE69333947D1 (de) Heteromorphe Schwämme mit Wirkstoffen
NO20074292L (no) Anvendelse av buprenorfin i polymermatriks og leveringssystemer
DK0754032T3 (da) Flydende frigivelsessammensætninger
GB9212511D0 (en) Pharmaceutical compositions
DE69523044D1 (de) Block- und pfropfcopolymere und dazu gehöriges verfahren
ATE306251T1 (de) Verwendung eines biologisch abbaubaren polymers
DE69434258D1 (de) Mikroverkapselte 1,2-benzazole
ATE263579T1 (de) Abgabe von polyethylene glycol-molekül- konjugaten aus abbaubarem hydrogel
PT1006935E (pt) Sistema de entrega controlada liquido de alta viscosidade
AU2740797A (en) Androstene derivatives
DE69129696D1 (de) Polymeres arzneimittelabgabesystem
TR200103427T2 (tr) Integrinlerin reseptörlerine bağlanmasını engelleyen propanoik asit türevleri.
TR200102107T2 (tr) Tümör nekroz faktör antagonistleri ve endometriozda kullanımları.
ATE212829T1 (de) Feste, wasserfreie, pharmazeutische zubereitungen für vaginale verwendung
ES2103493T3 (es) Uso de parathormona, de sus fragmentos biologicamente activos y de peptidos relacionados para el tratamiento del embarazo.
AU8025998A (en) Biologically active materials
DE69634662D1 (de) Schmerzlindernde verwendung von n-l-alpha-aspartyl-l-phenylalanine-1-methylester
CO4960657A1 (es) Composicion farmaceutica
DE59703910D1 (de) Verwendung von asparaginsäure-haltigen polymeren in mit bioziden versetzten kühlkreisläufen
ATE206911T1 (de) Feste arzneimittelform mit polymerem material verteiltem wirkstoff
ATE235909T1 (de) Biologisch kompatible und biologisch abbaubare zubereitungen enthaltend hyaluronsäure und deren derivate zur behandlung von geschwüren im verdauungsapparat

Legal Events

Date Code Title Description
8364 No opposition during term of opposition